Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
MRNA, cancer vaccine
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor cancers.
Moderna mRNA mpox vaccine shows promise in animal study
An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease symptoms and duration, according to an animal study published in the
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is targeted for patients with lung cancer,
New Cancer Vaccine Offers Hope: Early Trials Of mRNA Vaccine Show Encouraging Results
Modernas new cancer vaccine, mRNA-4359, shows promising results in early clinical trials. Utilizing mRNA technology, similar to its Covid-19 vaccine, this treatment primes the immune system to identify and destroy cancer cells.
New mRNA Cancer Vaccine Shows Promise in Early Trial
A new mRNA vaccine developed by Moderna has shown potential in stimulating the immune system to fight advanced cancer, according to results from an initial trial. The vaccine, called mRNA-4359, is designed for patients with advanced melanoma,
Cancer Breakthrough: New Vaccine Stops Tumours In Their Tracks, Prevents New Disease
A new cancer vaccine could stop tumours growing in patients with advanced disease, researchers say. Designed to prime the body to recognize and fight cancer cells, the jab could stimulate the immune system to treat the deadly disease more effectively,
ESMO: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer killing cells.
Revolutionary cancer vaccine targeting advanced tumors shows promise in early trials
The vaccine, named mRNA-4359, was developed by Moderna and is aimed at people with advanced melanoma, lung cancer, and a range of other solid tumor cancers
BioSpace
6d
5 Late-Stage mRNA Vaccines to Watch
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...
10d
on MSN
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
4d
on MSN
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...
2d
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...
5d
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...
KALW
12d
Whatever happened to ... the Brazilian besties creating an mRNA vaccine as a gift to the world
Frustrated when Brazil could not get COVID vaccines, two Brazilian doctors (who have been best friends since college) decided ...
8d
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...
3d
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...
2d
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback